[Interstitial pneumonitis associated with sirolimus administration in a renal transplantation patient: a clinical case].
Sirolimus is an immunosuppressive drug which has proved its effectivity to reduce the incidence of acute rejection in renal transplantation receptors. As this drug lacks nephrotoxic effects, its simultaneous use with other anticalcineurinic drugs allows the use of reduced doses. Thrombocytopenia and hyperlipidemia are the best known side-effects of sirolimus administration. Alterations in hepatic biochemistry results are also common. Some instances of interstitial pneumonitis associated to its use have been recently reported. In this paper we present a clinical case related to this rare but already confirmed adverse side-effect, which apart from the other more common nosologies occurring in immunosuppressed patients, should be taken into account in the differential diagnosis of interstitial pneumonitis in patients who are being administered this drug.
Martínez
M
M
Servicio de Nefrología, Hospitales Universitarios Virgen del Rocío, Sevilla.
González Roncero
F M
FM
López
M
M
Toro
J
J
Valdivia
M A
MA
Pereira
P
P
Gentil
M A
MA
Rodríguez Algarra
G
G
Mateos
J
J
D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004232:Diuretics / Q000627:therapeutic use; D017292:Doxazosin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015738:Famotidine / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000175:diagnosis; D011183:Postoperative Complications / Q000139:chemically induced* / Q000175:diagnosis; D011241:Prednisone / Q000627:therapeutic use; D020123:Sirolimus / Q000009:adverse effects*
D000961:Antilymphocyte Serum; D004232:Diuretics; D007166:Immunosuppressive Agents; D015738:Famotidine; D005665:Furosemide; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D017292:Doxazosin; D011241:Prednisone; D020123:Sirolimus